Trial · NCT07905820
Vaginal Platelet-Rich Plasma and Vaginal Histology in Genitourinary Syndrome of Menopause
NCT07905820, Not applicable, Completed, National and Kapodistrian University of Athens
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vaginal Platelet-Rich Plasma and Vaginal Histology in Genitourinary Syndrome of Menopause. Trials, record NCT07905820. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905820
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vaginal Platelet-Rich Plasma and Vaginal Histology in Genitourinary Syndrome of Menopause
- NCT number
- NCT07905820
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- National and Kapodistrian University of Athens
- Conditions
- Genitourinary Syndrome of Menopause (GSM)
- Interventions
- Autologous Platelet-Rich Plasma (PRP), 0.9% sodium chloride (normal saline)
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Epithelial thickness | Week 8 (4 weeks after the second treatment session), at the time of prolapse surgery | Mean vaginal epithelial thickness (μm) measured by digital morphometry on hematoxylin and eosin-stained sections (mean of five non-overlapping fields per biopsy, ×10), compared between PRP-treated, saline-treated and no intervention sites within participants. |
| Primary | Vascular density of the lamina propria | Week 8 (4 weeks after the second treatment session), at the time of prolapse surgery | Number of factor VIII-positive vessels per mm² of lamina propria on immunohistochemistry (mean of five non-overlapping fields per biopsy, ×10), compared between PRP-treated, saline-treated and no intervention sites within participants. |
| Secondary | Epithelial glycogen area fraction | Week 8 (4 weeks after the second treatment session), at the time of prolapse surgery | Glycogen area fraction (%) of the epithelium on periodic acid-Schiff-stained sections (mean of five fields, ×10), compared between PRP-treated, saline-treated and no intervention sites within participants. |
| Secondary | Epithelial proliferative activity | Week 8 (4 weeks after the second treatment session), at the time of prolapse surgery | Density of Ki-67-positive basal and parabasal epithelial cells (cells/mm² of epithelium), compared between PRP-treated, saline-treated and no intervention sites within participants. |
| Secondary | Subepithelial papillae | Week 8 (4 weeks after the second treatment session), at the time of prolapse surgery | Number of subepithelial papillae per microscopic field at ×10 (mean of five fields), compared between PRP-treated, saline-treated and no intervention sites within participants. |
| Secondary | Collagen Architecture Score | Week 8 (4 weeks after the second treatment session), at the time of prolapse surgery | Study-specific semiquantitative score on Masson's trichrome-stained sections (×20): trabecular organization, bundle thickness/definition and stromal connectivity, each graded 0-2 (field score 0-6; higher scores indicate more organized collagen); biopsy score is the mean of five fields. Compared between PRP-treated, saline-treated and no intervention sites within participants. |
| Other | Histological outcomes by baseline and clinical characteristics (exploratory) | Week 8 (4 weeks after the second treatment session), at the time of prolapse surgery | Hypothesis-generating subgroup analyses of the primary outcomes (PRP vs saline vs no intervention) by baseline atrophy severity ; vaginal maturation value; vaginal pH; age; BMI and sexual activity. |
| Other | Histological outcomes by anatomical site (exploratory) | Week 8 (4 weeks after the second treatment session), at the time of prolapse surgery | Primary and secondary histological outcomes compared between anterior and posterior vaginal wall biopsy sites, irrespective of treatment allocation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905820
GET https://conductscience.org/api/trials/v1/NCT07905820/registered